| Symbol | KNSA |
|---|---|
| Name | KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 105 PICCADILLY,SECOND FLOOR, LONDON, W1J 7NJ, Bermuda |
| Telephone | +44 781 431 - 9100 |
| Fax | — |
| — | |
| Website | https://www.kiniksa.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001730430 |
| Description | Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksas portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Additional info from NASDAQ: Additional info from NASDAQ: |
Paolini John F. 🟡 adjusted position in 58.4K shares (1 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $54.04 ($4.3M) Transaction Date: May 01, 2026 | Filing ID: 000008
Read more📋 Paolini John F. (Officer) plans to sell 58K shares of Kiniksa Pharmaceuticals International, plc (at $53.71 each, total $3.1M) Filed: May 01, 2026 | ID: 000432
Read morePatel Sanj K 🟡 adjusted position in 48.6K shares (1 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $54.02 ($5.6M) Transaction Date: May 01, 2026 | Filing ID: 000008
Read moreQuart Barry D 🟡 adjusted position in 13.1K shares (1 derivative) of Kiniksa Pharmaceuticals International, plc (KNSA) at $50.10 ($1.0M) Transaction Date: Apr 28, 2026 | Filing ID: 000010
Read more📋 Patel Sanj K (Officer) plans to sell 345K shares of Kiniksa Pharmaceuticals International, plc (at $51.60 each, total $17.8M) Filed: Apr 28, 2026 | ID: 000422
Read more(10% Negative) KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) Announces Delay in inhibition Trials for recurrent pericarditis Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreKiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Read moreKiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
Read moreNew Form ARS - Kiniksa Pharmaceuticals International, plc <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001104659-26-044418 <b>Size:</b> 3 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07288216 | Transition to KPL-387 Monotherapy Dosing & Administration Study | Phase2 | Recurrent Pericarditis | Recruiting | 2026-03-25 | 2029-12-31 | ClinicalTrials.gov |
| NCT07010159 | Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase2 | Pericarditis | Recruiting | 2025-07-25 | 2029-12-31 | ClinicalTrials.gov |
| NCT06531395 | A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With … | Phase2 | Sjögrens Disease | Terminated | 2024-07-17 | 2025-05-01 | ClinicalTrials.gov |
| NCT05198310 | Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Partic… | Phase2 | Arthritis, Rheumatoid | Completed | 2021-12-14 | 2024-05-06 | ClinicalTrials.gov |
| NCT04687358 | REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adul… | — | Recurrent Pericarditis | Active_Not_Recruiting | 2021-03-16 | 2029-03-01 | ClinicalTrials.gov |
| NCT04463004 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… | Phase2 | COVID-19 | Completed | 2020-09-02 | 2020-11-30 | ClinicalTrials.gov |
| NCT04447469 | Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona… | Phase2 | COVID | Completed | 2020-07-28 | 2022-01-14 | ClinicalTrials.gov |
| NCT04492514 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… | Phase2 | COVID 19 | Completed | 2020-05-20 | 2020-11-16 | ClinicalTrials.gov |
| NCT04399980 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pne… | Phase2 | COVID 19 | Completed | 2020-05-20 | 2021-04-23 | ClinicalTrials.gov |
| NCT04497662 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynam… | Phase1 | Healthy Volunteers | Completed | 2019-10-22 | 2021-03-02 | ClinicalTrials.gov |
| NCT03858634 | A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing… | Phase2 | Chronic Idiopathic Urticaria | Completed | 2019-05-29 | 2020-06-08 | ClinicalTrials.gov |
| NCT03816891 | Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reduci… | Phase2 | Prurigo Nodularis | Completed | 2019-03-11 | 2023-08-24 | ClinicalTrials.gov |
| NCT03737110 | Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants… | Phase3 | Recurrent Pericarditis | Completed | 2019-01-07 | 2022-06-30 | ClinicalTrials.gov |
| NCT03827018 | KPL-301 for Subjects With Giant Cell Arteritis | Phase2 | Giant Cell Arteritis | Completed | 2018-09-20 | 2020-11-25 | ClinicalTrials.gov |
| NCT03980522 | A Pilot Study of KPL-914 in Recurrent Pericarditis | Phase2 | Recurrent Pericarditis | Completed | 2018-01-24 | 2019-05-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| Placebo | Other | Phase PHASE2 | COVID 19 | COMPLETED | NCT04492514 |
| Mavrilimumab | Other | Phase PHASE2 | COVID 19 | COMPLETED | NCT04492514 |
| Placebo | Other | Phase PHASE2 | Sjögrens Disease | TERMINATED | NCT06531395 |
| Abiprubart | Other | Phase PHASE2 | Sjögrens Disease | TERMINATED | NCT06531395 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04497662 |
| KPL-404 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04497662 |
| Placebos | Other | Phase PHASE2 | COVID 19 | COMPLETED | NCT04399980 |
| Mavrilimumab | Other | Phase PHASE2 | COVID 19 | COMPLETED | NCT04399980 |
| KPL-914 | Other | Phase PHASE2 | Recurrent Pericarditis | COMPLETED | NCT03980522 |
| Placebos | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04463004 |
| Mavrilimumab | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04463004 |
| Placebo | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| Rilonacept | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| Placebo | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| Rilonacept | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| Placebo | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| Rilonacept | Other | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| prednisone | Other | Phase PHASE2 | Giant Cell Arteritis | COMPLETED | NCT03827018 |
| placebo | Other | Phase PHASE2 | Giant Cell Arteritis | COMPLETED | NCT03827018 |
| mavrilimumab | Other | Phase PHASE2 | Giant Cell Arteritis | COMPLETED | NCT03827018 |
| Placebo | Other | Phase PHASE2 | COVID | COMPLETED | NCT04447469 |
| mavrilimumab | Other | Phase PHASE2 | COVID | COMPLETED | NCT04447469 |
| Placebo | Other | Phase PHASE2 | Chronic Idiopathic Urticaria | COMPLETED | NCT03858634 |
| KPL-716 | Other | Phase PHASE2 | Chronic Idiopathic Urticaria | COMPLETED | NCT03858634 |
| Placebo | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT05198310 |
| KPL-404 | Other | Phase PHASE2 | Arthritis, Rheumatoid | COMPLETED | NCT05198310 |
| Placebo | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT03816891 |
| Vixarelimab | Other | Phase PHASE2 | Prurigo Nodularis | COMPLETED | NCT03816891 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| Placebo | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-387 | Other | Phase PHASE2 | Pericarditis | RECRUITING | NCT07010159 |
| KPL-914 | DRUG | Phase PHASE2 | Recurrent Pericarditis | COMPLETED | NCT03980522 |
| Rilonacept | DRUG | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| KPL-387 | DRUG | Phase PHASE2 | Recurrent Pericarditis | RECRUITING | NCT07288216 |
| Abiprubart | DRUG | Phase PHASE2 | Sjögrens Disease | TERMINATED | NCT06531395 |
| Placebo | DRUG | Phase PHASE3 | Recurrent Pericarditis | COMPLETED | NCT03737110 |
| mavrilimumab | DRUG | Phase PHASE2 | COVID | COMPLETED | NCT04447469 |